Evidence mapPaperPMID 34513071Full record

ReviewSovremennye tekhnologii v meditsine2021

Clinical Use of Progestins and Their Mechanisms of Action: Present and Future (Review).

T A Fedotcheva

Registry-linked trialAbstract readReview
In one paragraph

Review in Sovremennye tekhnologii v meditsine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07477808 (A Prospective, Randomized, Parallel-Controlled Clinical Study of Megestrol Acetate Oral Suspension for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07477808 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Prospective, Randomized, Parallel-Controlled Clinical Study of Megestrol Acetate Oral Suspension for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

TypeinterventionalSponsorHunan Province Tumor HospitalRan2026 to 2029Enrolled116ConditionsNon-small Cell Lung CancerArmsNanocrystalline Megestrol Acetate Oral Suspension, PD-1/L1 inhibitor combined with chemotherapy
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. The crosstalk between ubiquitination and endocrine therapy.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  11. Article
  12. Review
  13. Progesterone in gender-affirming therapy of trans women.World journal of biological chemistry · 2022
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

T A FedotchevaSenior Researcher, Research Laboratory of Molecular Pharmacology, Pirogov Russian National Research Medical University, 1 Ostrovitianova St., Moscow, 117997, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review summarizes the current opinions on the mechanisms of action of nuclear, mitochondrial, and membrane progesterone receptors. The main aspects of the pharmacological action of progestins have been studied. Data on the clinical use of gestagens by nosological groups are presented. Particular attention is paid to progesterone, megestrol acetate, medroxyprogesterone acetate due to broadening of their spectrum of action. The possibilities of using gestagens as neuroprotectors, immunomodulators, and chemosensitizers are considered.

Indexed as

MegestrolProgestinsMedroxyprogesteroneMedroxyprogesterone AcetateProgesteroneMedroxyprogesteroneMedroxyprogesterone AcetateMegestrolProgesteroneProgestinsgestagensmedroxyprogesterone acetatemegestrol acetateprogesteroneprogesterone receptors

Identifiers

PMID34513071
PMCPMC8353691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.